Formamide

Formamide

SCHEMBL447576

Cc1ccc(C)o1.NC=O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.65
MAPT P10636 6/20 0.40
ALDH1A1 P00352 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NQO1 P15559 1/20 0.39
ALOX5 P09917 4/20 0.36
PKM P14618 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
CHRM2 P08172 2/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CYP2C9 P11712 1/20 0.36
CHRM3 P20309 1/20 0.36
KLK7 P49862 1/20 0.35
HTT P42858 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31103 0.80
Ammonia Solution, Strong SCHEMBL3583090 0.77
Bicarbonate SCHEMBL9195144 0.73 TDP1 (0.69) TDP1MAPTALDH1A1MEN1KMT2A
5-Methylfurfural SCHEMBL51606 0.72
P-Xylene SCHEMBL28238851 0.71 CYP2A6 (0.58) TDP1ALDH1A1MEN1KMT2APKM
P-Xylene SCHEMBL16684588 0.71 TDP1 (0.79) TDP1MAPTALDH1A1MEN1KMT2A
Dimethylamine SCHEMBL3189287 0.71 TDP1 (0.79) TDP1MAPTALDH1A1MEN1KMT2A
SCHEMBL25660525 0.71 ALOX5 (0.42) TDP1MAPTALDH1A1MEN1KMT2A
Bicarbonate SCHEMBL10415332 0.71 TDP1 (0.65) TDP1MAPTALDH1A1MEN1KMT2A
5-Methylfurfural SCHEMBL4463513 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US claimed
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES APP, BACE1, PSEN1 TDP1 200/4885MAPT 14/4885ALDH1A1 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.